RCKT Chief Science Officer reports 2,545-share stock sale

Rhea-AI Filing Summary

Rocket Pharmaceuticals insider trading update: A company officer reported a small sale of common stock. On 11/18/2025, the Chief Science & Gene Therapy Officer disposed of 2,545 shares of Rocket Pharmaceuticals, Inc. (RCKT) common stock at a price of $2.983 per share in an open market sale. After this transaction, the reporting person beneficially owns 299,064 shares, which include Restricted Stock Units that convert into common stock on a one-for-one basis.

Insider Trade Summary

Net Seller: 2,545 shares ($7,592)

Net Sell 1 txn

Insider Schwartz Jonathan David

Role See Remarks

Sold 2,545 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,545	$2.983	$8K

Holdings After Transaction: Common Stock — 299,064 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schwartz Jonathan David

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NJ 08512

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	11/18/2025		S		2,545	D	$2.983	299,064	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Remarks:

Chief Science & Gene Therapy Officer

	/s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RCKT report on this Form 4?

The filing reports that the Chief Science & Gene Therapy Officer sold 2,545 shares of Rocket Pharmaceuticals common stock on 11/18/2025.

At what price were the Rocket Pharmaceuticals (RCKT) shares sold?

The 2,545 common shares were sold at a price of $2.983 per share.

How many Rocket Pharmaceuticals (RCKT) shares does the insider own after the sale?

Following the reported transaction, the insider beneficially owns 299,064 shares of Rocket Pharmaceuticals common stock.

Who is the reporting person on this Rocket Pharmaceuticals Form 4?

The reporting person is the company’s Chief Science & Gene Therapy Officer, as noted in the remarks section.

Does the RCKT insider’s holdings include Restricted Stock Units (RSUs)?

Yes. The holdings include Restricted Stock Units (RSUs) that convert to Rocket Pharmaceuticals common stock on a one-for-one basis.

Is this Form 4 filed for one or multiple reporting persons for RCKT?

The Form 4 is filed by one reporting person, as indicated in the filing.